GlassScriptPhysician profile
Kristen Resetar
NPI 1912378407
$14,919.10
in general payments reported to CMS, 2019-2025
44 companies · $3,075 in 2025
The $3,075 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,448 · 2022: $4,124 · 2023: $1,891 · 2024: $2,381 · 2025: $3,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,484 · Travel and Lodging: $751 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,484.08 |
| Travel and Lodging | $751.18 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,092.14 | 2021-2025 | |
| Livanova USA, INC. | $2,949.54 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $1,310.27 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $881.27 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $702.14 | 2022 | |
| Amgen INC. | $585.69 | 2021-2025 | Aimovig, Uplizna |
| Genzyme Corporation | $439.63 | 2021-2025 | |
| Lilly USA, LLC | $434.38 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Jazz Pharmaceuticals INC. | $405.74 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $402.93 | 2021 | |
| Biogen, INC. | $372.90 | 2021-2024 | Skyclarys |
| Genentech USA, INC. | $350.03 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $223.87 | 2021-2025 | Nuplazid |
| Sk Life Science, INC. | $206.63 | 2021-2024 | |
| Eisai INC. | $200.70 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $194.99 | 2021-2024 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $154.68 | 2021-2024 | Nourianz |
| Avadel Cns Pharmaceuticals, LLC | $148.18 | 2023-2024 | Lumryz |
| Celgene Corporation | $135.04 | 2021-2023 | Zeposia |
| Neurelis, INC. | $123.93 | 2021 | |
| Csl Behring | $122.89 | 2021-2024 | Hizentra |
| Merz Pharmaceuticals, LLC | $120.56 | 2021 | |
| Argenx US, INC. | $116.06 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $112.47 | 2021-2024 | Onpattro |
| Emd Serono, INC. | $102.25 | 2021-2025 | Mavenclad |
| Lundbeck LLC | $99.53 | 2021-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $99.01 | 2021-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $94.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.99 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $83.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.00 | 2021-2025 | Hyqvia |
| Tg Therapeutics, INC. | $61.26 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $60.27 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $55.95 | 2021-2023 | Lyvispah, Rytary |
| Ipsen Biopharmaceuticals, INC | $55.32 | 2021 | |
| Banner Life Sciences, LLC | $42.95 | 2021-2022 | |
| Grifols USA, LLC | $42.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.15 | 2021-2022 | |
| Ge Healthcare | $29.41 | 2022-2025 | |
| Tanabe Pharma America, INC. | $27.09 | 2021-2023 | |
| Allergan, INC. | $23.40 | 2022 | |
| Ucb, INC. | $21.23 | 2025 | Rystiggo |
| Mdd US Operations, LLC | $19.82 | 2021 | |
| Merck Sharp & Dohme LLC | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Resetar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.